Novartis Shares Tumble as Two Experimental Drugs Fail Late-Stage Trials

ZURICH — Novartis AG announced on Thursday that two of its key experimental therapies failed to meet primary endpoints in late-stage clinical trials, dealing a significant blow to the pharmaceutical giant's pipeline and sending its shares into a decline. The setbacks involve del-desiran, intended for myotonic dystrophy type 1, and pelacarsen, a candidate aimed at reducing cardiovascular events.

The Swiss drugmaker stated that del-desiran did not demonstrate a statistically significant improvement over placebo in patients with myotonic dystrophy type 1. This genetic disorder causes progressive muscle wasting and weakness, representing a rare disease market where effective treatments are scarce. The failure marks a major disappointment for Novartis, which had invested heavily in the compound as a potential breakthrough for a condition with limited therapeutic options.

Simultaneously, pelacarsen failed to achieve its primary goal of reducing cardiovascular events in its study population. The drug was designed to lower levels of apolipoprotein C-III, a protein linked to elevated triglycerides and increased risk of heart disease. Despite earlier promising data from Phase 2 studies, the late-stage results indicated that the treatment did not deliver the necessary clinical benefit to justify regulatory approval.

The announcement sent ripples through global financial markets, with Novartis stock falling sharply on the New York Stock Exchange and European exchanges following the news. As one of the world's largest pharmaceutical companies, Novartis relies heavily on a robust pipeline of new drugs to offset patent expirations on its existing blockbuster medicines. The simultaneous failure of two high-profile candidates raises concerns about the company's near-term growth prospects and its ability to replace revenue from aging products.

Novartis management indicated that it would not pursue regulatory approval for either drug based on the current data. The company stated it is reviewing next steps, including potential re-evaluation of trial designs or alternative indications, though no immediate plans were outlined. Investors are now left wondering how these failures will impact the company's overall R&D strategy and whether other assets in its pipeline face similar risks.

The results underscore the high stakes and inherent unpredictability of drug development, particularly in complex areas such as rare genetic disorders and cardiovascular disease. While Novartis maintains a diversified portfolio, the loss of two potential revenue streams at this stage represents a substantial financial and strategic setback. Analysts are expected to adjust their forecasts for the company in the coming days as the full implications of the trial failures become clear.

Questions remain regarding the specific biological mechanisms that led to these failures and whether Novartis will attempt to salvage either program through further research or by exploring different patient populations. The pharmaceutical sector watches closely as the company navigates this challenging period.